Ashley McEvoy stepped into her role as President and Chief Executive Officer of Insulet in April 2025, leading the company at a pivotal moment in diabetes‑care innovation.
Meet Ashley McEvoy: leader with unmatched experience
Ashley McEvoy brings nearly three decades of healthcare leadership, most recently serving as Executive Vice President and Worldwide Chairman of Johnson & Johnson’s MedTech business, which in 2023 employed 60,000 people and generated over $30 billion in revenue. She rose through roles including Group Chairman of Consumer Medical Devices, Vision and Diabetes Care divisions, Worldwide President of Ethicon, and McNeil Consumer Healthcare leader.
Early Life and Education of Ashley McEvoy
Ashley McEvoy was born and raised in the United States, where she developed an early interest in healthcare and leadership. While specific details about her early childhood remain private, those who’ve worked with her often describe her as intellectually curious, driven, and purpose-oriented from a young age. These qualities would later shape her long and successful career in the healthcare industry.
McEvoy pursued higher education at Duke University, where she earned her Bachelor of Arts degree in Public Policy Studies. Her time at Duke provided her with a strong foundation in strategic thinking, policy analysis, and ethics disciplines that would prove valuable as she navigated complex leadership roles in both consumer health and medical technology. Duke’s interdisciplinary approach helped sharpen her communication and decision-making skills, giving her a competitive edge early in her career.
Even during her college years, McEvoy was known for blending analytical thinking with a people-centered mindset, qualities that would define her professional leadership style. Her education laid the groundwork for what would become a remarkable journey across the healthcare landscape culminating in her current role as President and CEO of Insulet.
Transition at Insulet
On April 28, 2025, Insulet’s Board appointed Ashley McEvoy as President & CEO, effective immediately. She succeeds Jim Hollingshead, who stepped down but will remain as consultant for a smooth transition. This change came during a strong first‑quarter performance, with Insulet expecting to exceed guidance and raising its full‑year outlook.
Vision for growth and innovation
Ashley McEvoy has stated that “Insulet has massive, untapped growth potential, a talented team, unparalleled pharmacy channel access … deeply loyal customers” and sees opportunities to drive global expansion, innovate in product solutions, and deliver shareholder value.
Bold track record at J&J
At Johnson & Johnson she led major business transformation accelerating MedTech revenue from roughly 1.5% to 7.8%, deploying $22 billion of capital into faster‑growth initiatives (heart failure, vision, robotics), and doubling the value of the new‑product pipeline. Her strategic acumen earned her recognition on FORTUNE’s “Future Fortune 500 CEOs” and “Most Powerful Women,” Forbes’ CEO NEXT, and other leadership lists.
Unique position for Insulet’s Omnipod platform
Insulet, best known for its Omnipod tubeless insulin pump that delivers insulin via a wearable pod up to three days, has positioned itself as a leader in automated insulin delivery (AID). The Omnipod 5 system launched under prior leadership and was the first AID pump approved in the U.S. for Type 2 diabetes as well as Type 1 diabetes. With Ashley McEvoy at the helm, Insulet aims to scale Omnipod globally and broaden its impact in both diagnostics and drug‑delivery applications.
Leadership style and board roles
Known for authenticity and strategic clarity, Ashley McEvoy blends consumer insight with medical‑technology leadership. Since 2023, she has served on the Board of Directors at Procter & Gamble and previously served on the Board of Trustees at the Children’s Hospital of Philadelphia. She is recognized for fostering inclusive teams, market‑driven innovation, and operational excellence.
Why this matters
Ashley McEvoy’s arrival signals a powerful new phase for Insulet. She inherits a company with rising revenues 2024 saw Insulet generate around $2.1 billion in revenue, up 22% year over year and a global leadership position in AID. Her experience scaling med‑tech businesses, entering new markets, and building innovation pipelines aligns well with Insulet’s next chapter: expanding in Type 2 diabetes, drug delivery beyond insulin, and geographic growth.
What to watch ahead
- First‑quarter earnings call (May 8, 2025): Insights into performance drivers under Ms. McEvoy’s leadership.
- Rescheduled Investor Day: Originally set for June 5, now postponed to a later date due to the leadership transition.
- Strategic priorities: Enhancing pharmacy distribution, expanding into new geographies and therapeutic areas, investing in R&D, and deepening provider and consumer engagement.
Ashley McEvoy has taken charge at Insulet with a clear mandate accelerate growth, deepen innovation, and drive global expansion. Her med‑tech pedigree, deep experience in diabetes care, and reputation as a transformative executive give Insulet a powerful leader for this next phase. As she guides the company through rising momentum and broader market opportunities, Insulet stands poised to reshape its future under her leadership and continue transforming daily life for people with diabetes around the world.
